HANDOK Inc.
Financials
Valuation Metrics
HANDOK Inc.'s Market Cap is ₩1279B. At end of 2025 it was ₩1542B. Ranked #1072 of 2,436 in KR market (top 44%), #525 of 787 on KOSPI (top 67%), #127 of 234 in Pharmaceuticals, Biotechnology & Life Sciences (top 54%) by Market Cap.
Investment Metrics(as of 2026-08-04)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 127.86B KRW | KR#1,072/2,436 Sec#127/234 |
| Revenue | 550.69B KRW | KR#575/2,436 Sec#29/234 |
| Net Income | -3.10B KRW | KR—/2,436 Sec—/234 |
| Total Assets | 798.75B KRW | KR#537/2,436 Sec#30/234 |
| Net Assets | 267.90B KRW | KR#755/2,436 Sec#51/234 |
| Employees | 988 | KR#257/2,436 Sec#19/234 |
| Value | ||
| P/B | 0.48x | KR#758/2,436 Sec#29/234 |
| P/S | 0.23x | KR#439/2,436 Sec#8/234 |
| EV/EBITDA | 84.80x | KR#1,445/2,436 Sec#101/234 |
| FCF Yield | -7.73% | KR—/2,436 Sec—/234 |
| Profitability | ||
| ROE | -1.16% | KR#1,575/2,436 Sec#110/234 |
| ROA | -0.39% | KR#1,541/2,436 Sec#108/234 |
| Op. Margin | 1.03% | KR#1,473/2,436 Sec#107/234 |
| Revenue Growth | 12.98% | KR#815/2,436 Sec#72/234 |
| Financial Health | ||
| Debt Ratio | 198.15% | KR#1,707/2,436 Sec#189/234 |
| Total Debt | 376.94B KRW | KR#349/2,436 Sec#14/234 |
| FCF | -9.88B KRW | KR#1,709/2,436 Sec#147/234 |
| Cash | 21.64B KRW | KR#1,197/2,436 Sec#87/234 |
| Current Ratio | 0.77x | KR#2,061/2,436 Sec#198/234 |
| Net Debt/EBITDA | 62.36x | KR#1,545/2,436 Sec#110/234 |
| Dividend | ||
| Div. Yield | 2.21% | KR#838/2,436 Sec#44/234 |
| Div. Growth | 0.00% | KR—/2,436 Sec—/234 |
| Performance | ||
| 1Y Return | -19.91% | KR#1,261/2,436 Sec#104/234 |
| 1M Return | 25.37% | KR#91/2,436 Sec#3/234 |
| From 52W High | -30.98% | KR#433/2,436 Sec#28/234 |
| 1Y MDD | -45.84% | KR#739/2,436 Sec#60/234 |
| Trading | ||
| Volume | 12,020 shares | KR#2,064/2,436 Sec#204/234 |
| Foreign Own. | 2.39% | KR—/2,436 Sec—/234 |
| Per Share | ||
| EPS | -219 KRW | KR—/2,436 Sec—/234 |
| BPS | 20,493 KRW | KR#501/2,436 Sec#35/234 |
Company Info
Handok, a pharmaceutical company established in 1954 and listed on the securities market in 1976, transferred its healthcare product business division to Handok Healthcare Co., Ltd. It manufactures and sells professional and general medicines, including diabetes treatments like Amaryl, Tenelia, and Lantus, and hypertension treatments such as Aprovasc, Aprovel, and Coaprovel. The company also engages in medical device and diagnostic reagent sales, pharmaceutical contract manufacturing and quality control services, and real estate leasing. Handok is headquartered in Gangnam-gu, Seoul Metropolitan City.